| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CMM6; XRCC3;;XRCC3 |
| WB Predicted band size | Calculated MW: 38 kDa ; Observed MW: 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human XRCC3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于XRCC3抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *XRCC3 promotes homology-directed repair of DNA damage in mammalian cells*
**作者**: Pierce, A.J., et al.
**摘要**: 该研究利用XRCC3特异性抗体通过免疫印迹和免疫荧光技术，验证了XRCC3蛋白在DNA同源重组修复中的关键作用，发现其缺失会导致染色体不稳定性和辐射敏感性升高。
2. **文献名称**: *Expression of XRCC3 in breast cancer tissues and its clinical significance*
**作者**: Tamura, K., et al.
**摘要**: 研究通过免疫组化(使用抗XRCC3抗体)分析乳腺癌组织中XRCC3的表达水平，发现高表达与患者预后不良及化疗耐药性相关，提示其作为潜在生物标志物的价值。
3. **文献名称**: *DNA repair protein XRCC3 deficiency enhances glioblastoma radiosensitivity in vitro and in vivo*
**作者**: Wang, J., et al.
**摘要**: 利用XRCC3抗体进行Western blot和免疫沉淀实验，证明抑制XRCC3表达可增强胶质瘤细胞对放疗的敏感性，为靶向DNA修复通路的治疗策略提供依据。
---
以上文献展示了XRCC3抗体在DNA修复机制研究、癌症预后评估及治疗响应中的多样化应用。如需具体文献来源，建议通过PubMed或Google Scholar以标题及作者名为关键词进一步检索。
**Background of XRCC3 Antibody**
The XRCC3 (X-ray repair cross-complementing protein 3) antibody is a tool used to detect and study the XRCC3 protein, a critical component of the DNA repair machinery. XRCC3 belongs to the RAD51 family and plays a pivotal role in homologous recombination repair (HR), a high-fidelity pathway essential for correcting DNA double-strand breaks (DSBs) and maintaining genomic stability. It interacts with RAD51C to form the RAD51C-XRCC3 complex, which stabilizes replication forks, facilitates sister chromatid exchange, and ensures accurate repair of damaged DNA.
Dysregulation or mutations in XRCC3 are linked to genomic instability, increased cancer susceptibility (e.g., breast, ovarian, and lung cancers), and hypersensitivity to DNA-damaging agents like ionizing radiation or chemotherapeutics. Researchers utilize XRCC3 antibodies in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression levels, subcellular localization, and its role in cancer progression or therapy resistance.
These antibodies are also valuable in studying the molecular mechanisms of DNA repair pathways and evaluating XRCC3 as a potential biomarker for predicting treatment outcomes in oncology. Their development and validation contribute to advancing personalized medicine and targeted therapies aimed at DNA damage response vulnerabilities.
×
